Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes

Details for Australian Patent Application No. 2006334733 (hide)

International Classifications

Event Publications

4 September 2008 PCT application entered the National Phase

PCT publication WO2007/079916 Priority application(s): WO2007/079916

16 July 2009 Assignment before Grant

Merck Patent GmbH The application has been assigned to POXEL SAS

12 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.